Both in Biotechnology
Lineage Cell Therapeutics vs ProKidney
Over the past year LCTX returned −47.9% and PROK returned −57.7%; their daily moves had a correlation of 0.38.
LCTX −47.9% PROK −57.7%Growth of $1, one year, split-adjusted
| Metric | LCTX | PROK |
|---|---|---|
| Price | $1.00 | $1.30 |
| Market cap | $252.9M | $270.6M |
| Today | −2.91% | −11.90% |
| 1 month | +10.6% | −24.3% |
| 6 months | −34.6% | −32.9% |
| Year to date | −40.1% | −42.2% |
| 1 year | −41.5% | −58.2% |
| Revenue growth (YoY) | −61.3% | −32.1% |
| Gross margin | 100.0% | 100.0% |
| Net margin | 138.6% | −18948.0% |
| P/E (TTM) | — | — |
| Price / sales | 19.3× | 330.8× |
| Net cash | $50.8M | $181.6M |
| Dividend yield | — | — |
| Volatility (60d) | 52.9% | 80.3% |
| Short % of float | 12.9% | 27.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).